tiprankstipranks
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX

Vertex Pharmaceuticals (VRTX) Stock Price & Analysis

5,232 Followers

VRTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$320.01 - $449.91
Previous Close$447.53
Volume917.62K
Average Volume (3M)1.03M
Market Cap
$116.16B
Enterprise Value$106.04B
Total Cash (Recent Filing)$10.17B
Total Debt (Recent Filing)$721.30M
Price to Earnings (P/E)29.0
Beta0.60
Aug 01, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.41
Shares Outstanding258,053,387
10 Day Avg. Volume1,071,184
30 Day Avg. Volume1,032,287
Standard Deviation0.08
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.92
Price to Sales (P/S)42.39
Price to Cash Flow (P/CF)22.00
P/FCF Ratio23.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.41
Enterprise Value/Gross Profit12.32
Enterprise Value/Ebitda28.01
Forecast
Price Target Upside1.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22

Bulls Say, Bears Say

Bulls Say
Drug Approval PotentialThe recent submission of Vanzacaftor’s triple combination therapy for NDA could lead to approval and higher gross margins for Vertex.
Financial PerformanceVertex reported revenue of $2.69B, surpassing consensus estimates, coupled with a robust non-GAAP EPS, reflecting strong financial health.
Pipeline DevelopmentVertex is expanding its product pipeline, with promising developments such as the resumption of dosing in the VX-880 study and anticipated progress in multiple Phase 3 and Phase 2 trials.
Bears Say
Financial PerformanceInterest income, which contributed to the strong bottom line, is likely to drop off sharply in the second half of the year following the Alpine deal closure.
Future Growth ConcernsIt is currently unclear what the next material growth driver is for Vertex after CF, with premium valuation shares at a P/E multiple above the peer average.
Product LaunchInitial sales of Casgevy may start slower than expected, with revised estimates significantly lower than previous forecasts.
---

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

VRTX FAQ

What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $320.01 and its highest was $449.91 in the past 12 months.
    What is Vertex Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Vertex Pharmaceuticals’s upcoming earnings report date?
    Vertex Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 70 days.
      How were Vertex Pharmaceuticals’s earnings last quarter?
      Vertex Pharmaceuticals released its earnings results on May 06, 2024. The company reported $4.76 earnings per share for the quarter, beating the consensus estimate of $4.073 by $0.687.
        Is Vertex Pharmaceuticals overvalued?
        According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Vertex Pharmaceuticals pay dividends?
          Vertex Pharmaceuticals does not currently pay dividends.
          What is Vertex Pharmaceuticals’s EPS estimate?
          Vertex Pharmaceuticals’s EPS estimate is $4.17.
            How many shares outstanding does Vertex Pharmaceuticals have?
            Vertex Pharmaceuticals has 258,053,380 shares outstanding.
              What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
              Vertex Pharmaceuticals reported an EPS of $4.76 in its last earnings report, beating expectations of $4.073. Following the earnings report the stock price went up 1.923%.
                Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
                Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Antipodes Partners Ltd. It holds Vertex Pharmaceuticals’s shares valued at 79M.
                  ---

                  Company Description

                  Vertex Pharmaceuticals

                  Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
                  ---

                  VRTX Company Deck

                  ---

                  VRTX Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  VRTX Revenue Breakdown

                  90.63%90.63%4.82%3.30%1.25%
                  90.63% TRIKAFTA/KAFTRIO
                  4.82% KALYDECO
                  3.30% ORKAMBI
                  1.25% SYMDEKO/SYMKEVI
                  tipranks
                  ---

                  VRTX Stock 12 Month Forecast

                  Average Price Target

                  $455.20
                  ▲(1.12% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"324":"$324","551":"$551","380.75":"$380.8","437.5":"$437.5","494.25":"$494.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":550,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$550.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":455.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$455.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$325.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[324,380.75,437.5,494.25,551],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.08,412.5353846153846,423.9907692307692,435.44615384615383,446.90153846153845,458.35692307692307,469.8123076923077,481.2676923076923,492.7230769230769,504.17846153846153,515.6338461538462,527.0892307692308,538.5446153846153,{"y":550,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.08,405.2430769230769,409.4061538461538,413.5692307692307,417.7323076923077,421.8953846153846,426.05846153846153,430.22153846153844,434.38461538461536,438.5476923076923,442.7107692307692,446.87384615384616,451.0369230769231,{"y":455.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.08,395.2276923076923,389.3753846153846,383.5230769230769,377.6707692307692,371.8184615384615,365.9661538461538,360.11384615384617,354.26153846153846,348.40923076923076,342.55692307692306,336.7046153846154,330.8523076923077,{"y":325,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":341.7,"date":1684454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":333.78,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.18,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":340.48,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.1,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":360.62,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":376.2,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.16,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":416.5,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":424.68,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432.76,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":406.67,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.08,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Biogen
                  Gilead Sciences
                  Amgen
                  Regeneron

                  Best Analysts Covering VRTX

                  1 Year
                  Hartaj SinghOppenheimer
                  1 Year Success Rate
                  30/35 ratings generated profit
                  86%
                  1 Year Average Return
                  +14.11%
                  assigned a buy rating 14 days ago
                  Copying Hartaj Singh's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +14.11% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis